Insights into clonal and CBC changes at disease evolution among ccus patients
Yazan Jabban(Mayo Clinic), Aref Al‐Kali(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Cecilia Arana Yi(Mayo Clinic Hospital), Mithun Vinod Shah(Mayo Clinic in Arizona), Dragan Jevremović(Mayo Clinic in Arizona), James M. Foran(Memorial Sloan Kettering Cancer Center), William H. Hogan(Mayo Clinic), Aasiya Matin(Mayo Clinic in Arizona), Hassan B. Alkhateeb(Mayo Clinic), Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Patricia T. Greipp(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), Kurt Bessonen(Mayo Clinic in Arizona), Rong He(Mayo Clinic in Arizona), Antoine N. Saliba(Mayo Clinic in Arizona), David S. Viswanatha(Mayo Clinic), Mehrdad Hefazi Torghabeh(Mayo Clinic)
Cited by 0
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
|Nature Reviews Nephrology|2018|544
Inherited antithrombin deficiency: a review
|Haemophilia|2008|396
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|297